DOBUTAMINE HYDROCHLORIDE IN DEXTROSE 5% Drug Patent Profile
✉ Email this page to a colleague
When do Dobutamine Hydrochloride In Dextrose 5% patents expire, and when can generic versions of Dobutamine Hydrochloride In Dextrose 5% launch?
Dobutamine Hydrochloride In Dextrose 5% is a drug marketed by Hospira and Baxter Hlthcare and is included in three NDAs.
The generic ingredient in DOBUTAMINE HYDROCHLORIDE IN DEXTROSE 5% is dobutamine hydrochloride. There are fourteen drug master file entries for this compound. Six suppliers are listed for this compound. Additional details are available on the dobutamine hydrochloride profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Dobutamine Hydrochloride In Dextrose 5%
A generic version of DOBUTAMINE HYDROCHLORIDE IN DEXTROSE 5% was approved as dobutamine hydrochloride by HOSPIRA on November 29th, 1993.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for DOBUTAMINE HYDROCHLORIDE IN DEXTROSE 5%?
- What are the global sales for DOBUTAMINE HYDROCHLORIDE IN DEXTROSE 5%?
- What is Average Wholesale Price for DOBUTAMINE HYDROCHLORIDE IN DEXTROSE 5%?
Summary for DOBUTAMINE HYDROCHLORIDE IN DEXTROSE 5%
US Patents: | 0 |
Applicants: | 2 |
NDAs: | 3 |
Finished Product Suppliers / Packagers: | 3 |
Raw Ingredient (Bulk) Api Vendors: | 59 |
Clinical Trials: | 117 |
DailyMed Link: | DOBUTAMINE HYDROCHLORIDE IN DEXTROSE 5% at DailyMed |
Recent Clinical Trials for DOBUTAMINE HYDROCHLORIDE IN DEXTROSE 5%
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Institutul de Urgenţă pentru Boli Cardiovasculare Prof.Dr. C.C. Iliescu | N/A |
Koç University | N/A |
Wuhan Union Hospital, China | Phase 2/Phase 3 |
See all DOBUTAMINE HYDROCHLORIDE IN DEXTROSE 5% clinical trials